Sandu Pharmaceuticals MD, chairman and AGM
BSE: 524703Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹35.31.
30 Oct: open ₹35.56, high ₹36.40, low ₹35.01
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹35 Cr3,677th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 19.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.80
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.78%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 4.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 5.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,591
Sandu Pharmaceuticals' chairperson and managing director is BALRAM VISWANATHAN, as filed for the quarter to Sep 2026. Its latest annual general meeting was on 11 Sep 2026.
Sandu Pharmaceuticals board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- Chairperson and managing directorBALRAM VISWANATHAN
- Company Secretary and Compliance OfficerPRATIKA MHAMBRAY
6 directors3 independent1 executive2 non-executive
- BALRAM VISWANATHAN · Chairperson and managing directorExecutive · joined Jul 2026 · reappointed Jul 2026 · 1 listed board · 1 committee seat
- AJIT RAJARAM KANTAKIndependent · joined Aug 2023 · reappointed Aug 2023 · 37 months as independent · 1 listed board · 1 as independent · 2 committee seats
- SHASHANK SANDUNon-executive · joined Jun 2011 · 1 listed board · 1 committee seat, 1 as chair
- VIJAY KOTTAPALLIIndependent · joined Aug 2024 · reappointed Aug 2024 · 25 months as independent · 1 listed board · 1 as independent · 1 committee seat, 1 as chair
- JAYSHREE BHASKER SANDUNon-executive · joined Sep 2024 · 1 listed board
- NEETI GUPTAIndependent · joined Jul 2026 · reappointed Jul 2026 · 2 months as independent · 1 listed board · 1 as independent · 1 committee seat
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
2 directors who left
- UMESH SANDU, left 19 Jun 2026: Others
- SHUBHADA SANDU, left 13 Feb 2025: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 11 Aug 20266 of 6 present3 independent · 30 days in between
- 11 Jul 20266 of 6 present3 independent · 66 days in between
- 5 May 20266 of 6 present3 independent
Audit Committee
Chair VIJAY KOTTAPALLI
AJIT RAJARAM KANTAK, BALRAM VISWANATHAN
- 11 Aug 20263 of 3 present2 independent · 97 days in between
- 5 May 20263 of 3 present2 independent
Nomination and remuneration committee
Chair AJIT RAJARAM KANTAK
SHASHANK SANDU, VIJAY KOTTAPALLI
- 11 Jul 20263 of 3 present2 independent
Stakeholders Relationship Committee
Chair SHASHANK SANDU
AJIT RAJARAM KANTAK, NEETI GUPTA
- 11 Aug 20263 of 3 present2 independent · 97 days in between
- 5 May 20263 of 3 present1 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- M/S Dileep and PrithviPeer-review certificate valid to Oct 2026
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Sandu Pharmaceuticals AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Sandu Pharmaceuticals dividend history
Annual general meeting, 11 Sep 2026
10,523 shareholders on the register on 4 Sep 2026; present: 4 promoters and 50 others; votes counted by SWAPNIL DIXIT / SWAPNIL J DIXIT & ASSOCIATES.The company's voting result
- TO ADOPT THE AUDITED STANDALONE FINANCIAL STATEMENTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2026.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 44.48% · promoters 59.63% · institutions 0.00% · other public 35.29%
- TO REAPPOINT SMT JAYSHREE SANDU (DIN: 07480177), WHO RETIRES BY ROTATION AS A DIRECTOROrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 36.86% · promoters 39.44% · institutions 0.00% · other public 35.29%
- TO DECLARE A DIVIDEND ON EQUITY SHARES FOR THE FINANCIAL YEAR ENDED MARCH 31, 2026Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 44.48% · promoters 59.63% · institutions 0.00% · other public 35.29%
- APPOINTMENT OF M/S. DAVE & DAVE, CHARTERED A CCOUNTANTS, AS STATUTORY AUDITORS OF THE COMPANY FOR THE TERM OF 05 YEARS.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 44.48% · promoters 59.63% · institutions 0.00% · other public 35.29%
- RATIFICATION OF COST AUDITOR'S REMUNERATIONOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 44.48% · promoters 59.63% · institutions 0.00% · other public 35.29%
- APPROVAL OF MATERIAL RELATED PARTY TRANSACTIONS WITH SANDU BROTHERS PRIVATE LIMITEDOrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 22.69% · promoters 1.67% · institutions 0.00% · other public 35.45%
- REDESIGNATION OF SHRI BALRAM VISWANATHAN (DIN: 10245195) AS CHAIRMAN AND MANAGING DIRECTORSpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 44.48% · promoters 59.63% · institutions 0.00% · other public 35.29%
- APPOINTMENT OF MRS NEETI MADAN KAPRE (DIN:06801264) AS AN NON EXECUTIVE INDEPENDENT DIRECTORSpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 44.48% · promoters 59.63% · institutions 0.00% · other public 35.29%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Tax disputes
Reported in the filing for the quarter to Sep 2026.
- Tax disputeDeputy Commissioner of State TaxSince 18 Nov 2022
The appeal filed before the First Appellate Authority on 03.02.2023 against the GST Demand of Rs 54,21,752 (inclusive of interest and penalty) is pending adjudication and the appellate proceedings are ongoing on this matterMoreLess
At the filing before: Demand of Rs.54,21,752/-(Inclusive of Interest & penalty) on account of difference in taxes/ITC in GST returns and against we have filed the Appeal before First Appellate Authority for FY 18-19 - Tax disputeDeputy Commissioner of State TaxSince 30 Jan 2025
The appeal filed before the joint commissioner of sale tax(SGST) on 12.04.2025 against the GST Demand of Rs 31,71,614 (inclusive of interest and penalty ) is pending adjudication and the appellate proceedings are ongoing in this matterMoreLess
At the filing before: Appeal is filed as on 12th Apr2025 to Joint Commisioner of Sale Tax(SGST)(Appeal) for FY 20-21 - Tax disputeDeputy Commissioner of State TaxSince 22 Dec 2025
Reply to concerned Notice is uploaded on GST portal as on 21/01/2026. As per Company’s own assessment and also based on legal advice, management is confident of favorable outcome for such notice if anyMoreLess
At the filing before: Notice received for intimating discrepancies with respect to Non reversal of ITC in GSTR3B as compared with GSTR9 of FY2023-24 for Rs.13,00,679/.
In the company's own words, from its latest governance filing.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- Yes
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Jun 2026. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere | Reason and comments |
|---|---|---|---|---|---|---|
| Preferential IssuesMar 2021, checked by NA | 2.64 | The Company shall use the proceeds from the proposed issue towards the revamping of the existing capital machinery, developing marketing infrastructure, civil work, required for major plant and machinery, purchase of new/ additional plant and machinery of the company, working capital requirement, investment in technologies and for general purpose which shall enhance the business of the Company | 2.64 | 2.64 | No | Audit committee: Audit Committee after review of the statement has noted and approved the same |
| Preferential IssuesFeb 2022 | 1.38 | The Company shall use the proceeds from the proposed issue towards the revamping of the existing capital machinery, developing marketing infrastructure, civil work, required for major plant and machinery, purchase of new/ additional plant and machinery of the company, working capital requirement, investment in technologies and for general purpose which shall enhance the business of the Company | 1.38 | 1.38 | No | NOTAPPLICABLEAudit committee: Audit Committee after review of the statement has noted and approved the same |
| Preferential IssuesJul 2022 | 1.32 | The Company shall use the proceeds from the proposed issue towards the revamping of the existing capital machinery, developing marketing infrastructure, civil work, required for major plant and machinery, purchase of new/ additional plant and machinery of the company, working capital requirement, investment in technologies and for general purpose which shall enhance the business of the Company | 1.32 | 0.47 | No | NOTAPPLICABLEAudit committee: Audit Committee after review of the statement has noted and approved the same |